Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis.
Retinoic acid (RA) and its various synthetic analogs affect mammalian cell growth, differentiation, and apoptosis. Whereas treatment of the human leukemia cell line HL60 with RA results in cellular differentiation, addition of the synthetic retinoid, N-(4-hydroxyphenyl) retinamide (HPR), induces HL60 cells to undergo apoptosis. Moreover, pretreatment of HL60 cells as well as other cell lines (i.e. NIH3T3 cells) with RA blocks HPR-induced cell death. In attempting to discover the underlying biochemical activities that might account for these cellular effects, we found that monodansylcadaverine (MDC), which binds to the enzyme (transamidase) active site of tissue transglutaminase (TGase), eliminated RA protection against cell death and in fact caused RA to become an apoptotic factor, suggesting that the ability of RA to protect against apoptosis is linked to the expression of active TGase. Furthermore, it was determined that expression of exogenous TGase in cells exhibited enhanced GTP binding and transamidation activities and mimicked the survival advantage imparted by RA. We tested whether the ability of this dual function enzyme to limit HPR-mediated apoptosis was a result of the ability of TGase to bind GTP and/or catalyze transamidation and found that GTP binding was sufficient for the protective effect. Moreover, excessive transamidation activity did not appear to be detrimental to cell viability. These findings, taken together with observations that the TGase is frequently up-regulated by environmental stresses, suggest that TGase may function to ensure cell survival under conditions of differentiation and cell stress.
Antonyak
M A
MA
Department of Molecular Medicine, Cornell University, Ithaca, New York 14853, USA.
Singh
U S
US
Lee
D A
DA
Boehm
J E
JE
Combs
C
C
Zgola
M M
MM
Page
R L
RL
Cerione
R A
RA
D016475:3T3 Cells; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002103:Cadaverine / Q000031:analogs & derivatives / Q000494:pharmacology; D002454:Cell Differentiation; D002467:Cell Nucleus / Q000378:metabolism; D002470:Cell Survival; D053938:DNA Fragmentation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017313:Fenretinide / Q000494:pharmacology; D018922:HL-60 Cells; D006801:Humans; D051379:Mice; D009154:Mutation; D019920:Photoaffinity Labels / Q000494:pharmacology; D015398:Signal Transduction; D013312:Stress, Physiological; D013997:Time Factors; D011503:Transglutaminases / Q000378:metabolism*; D014212:Tretinoin / Q000378:metabolism*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019920:Photoaffinity Labels; D017313:Fenretinide; D014212:Tretinoin; D011503:Transglutaminases; C008542:monodansylcadaverine; D002103:Cadaverine